Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095524 · ClinicalTrials.gov registry record · Phase 3
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00095524 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 300 participants.
The verdict
NCT00095524, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095524
The ClinicalTrials.gov registry entry for NCT00095524 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00095524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095524 about?
NCT00095524 is a clinical study titled "Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder". The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
What is the current status of trial NCT00095524?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-03. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00095524?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00095524?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.